[{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac's Coronavirus Vaccine Candidate Approved for Emergency Use in China- Source","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Yiling Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lianhua Qingwen Receives First International Approval for Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Yiling Pharmaceutical"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Trials of Sinovac Covid-19 Vaccine Show Promising Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinopharm","sponsor":"Beijing Institute of Biological Product","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UAE Ministry of Health and Prevention Announces Official Registration of Inactivated Covid-19 Vaccine Used in #4 Humanity Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinopharm"},{"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Grants Conditional Market Approval for Sinopharm CNBG\u2019S COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinopharm"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Vaccine 78% Effective in Brazil Trial, Experts Call for More Details","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Approves Use of CoronaVac Doses Partly Manufactured Locally","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thailand Approves Sinovac Vaccine Ahead of National Rollout","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino\u2019s Covid-19 Vaccine Receives Approval in Hungary for Emergency Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"Fosun Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fosun Submits Trial Data of Foreign Covid-19 Vaccine for State Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Fosun Pharmaceutical"},{"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$171.2 million","upfrontCash":"Undisclosed","newsHeadline":"CanSino Unit Gets USD171.2 Million to Build Covid-19 Vaccine Production Line","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNTech, Fosun Pharma Entering Into Term Sheet in Relation to Formation of a Joint Venture","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Fosun Pharmaceutical"},{"company":"Sinovant Sciences","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with CABP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sinovant Sciences"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO Validates Sinovac COVID-19 Vaccine for Emergency Use and Issues Interim Policy Recommendations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argentina Issues Emergency Approval to China's Single-Dose Cansino Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Infectious Diseases Published Data from Sinovac\u2019s Phase I\/II Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"company":"Shenzhen Kangtai Biological Products","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recombinant Covid-19 Vaccine (Adenovirus Vector) Licensed for Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Shenzhen Kangtai Biological Products"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Research on SINOVAC\u2019s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinopharm's COVID Booster Reverses Antibody Decline, Enhances Cell-Based Responses - Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinopharm"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preliminary Results Show SINOVAC\u2019s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Receives Request for Emergency Use of CanSino Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"company":"Ascletis Pharma","sponsor":"Phokam Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascletis Announces the Signing of a Purchase Agreement for Ritonavir Tablets with Phokam Pharmaceutical Import-Export Co., Ltd in Laos","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Key Data Results of the Phase III Global Multicenter Clinical Trial of Prokluamide in the Treatment of Non-Hospitalized COVID-19 Patients with Mild and Moderate Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"}]
Details:
The clinical trial will evaluate the immunogenicity and safety of one booster dose of the two candidate vaccines in adults who had received two booster doses of CoronaVac (Inactivated COVID-19 Vaccine), mRNA, or adenovirus vector COVID-19 vaccine.
Lead Product(s):
Inactivated COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: CoronaVac
Highest Development Status: Approved
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 06, 2022
Details:
COVID-19 vaccine (CoronaVac/Inactivated COVID-19 Vaccine) phase III clinical studies showed vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
Lead Product(s):
Inactivated COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: CoronaVac
Highest Development Status: Approved
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 03, 2022
Details:
Panflu (inactivated quadrivalent vaccine) is the first and only approved vaccine available in China against the H5N1 influenza virus, to provide protection against the H1N1 virus, also known as swine flu.
Lead Product(s):
Inactivated Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: Anflu
Highest Development Status: Approved
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 19, 2022
Details:
Prokalutamide can effectively reduce the hospitalization/mortality rate of new crown patients, especially for all patients who took the drug for more than 7 days, the corresponding protection rate reached 100%.
Lead Product(s):
Proxalutamide
Therapeutic Area: Infections and Infectious Diseases
Product Name: GT0918
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 06, 2022
Details:
Ritonavir oral tablet approved by China NMPA, is a component of oral direct-acting antiviral drug Paxlovid (Nirmatrelvir+ritonavir), an antiviral protease inhibitors for the treatment of COVID19.
Lead Product(s):
Ritonavir,Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases
Product Name: Paxlovid
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 03, 2022
Details:
Ritonavir oral tablet is a pharmacokinetic enhancer of various oral antiviral drugs against viral proteases. Ritonavir oral tablet is one of the components of the oral antiviral drug Paxlovid (Nirmatrelvir + ritonavir).
Lead Product(s):
Ritonavir
Therapeutic Area: Infections and Infectious Diseases
Product Name: Ritonavir-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Phokam Pharmaceutical
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
January 18, 2022
Details:
The Company’s COVID-19 pipeline currently includes (i) ritonavir oral tablet (100 mg), an authorized product, (ii) ASC10, an oral RNA dependent RNA polymerase (RdRp) inhibitor and (iii) ASC11, an oral 3-chymotrypsin like protease (3CLpro) inhibitor.
Lead Product(s):
Ritonavir
Therapeutic Area: Infections and Infectious Diseases
Product Name: ASC 09
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 03, 2022
Details:
Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide, a silent antagonist of the androgen receptor for treating COVID-19 in non-hospitalized COVID-19 patients.
Lead Product(s):
Proxalutamide
Therapeutic Area: Infections and Infectious Diseases
Product Name: GT0918
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 27, 2021
Details:
Convidicea (Ad5-nCoV) is a novel recombinant viral vector vaccine for COVID-19 produced in China. The single-dose vaccine was developed on CanSinoBIO's adenovirus-based viral vector vaccine technology platform.
Lead Product(s):
Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases
Product Name: Convidecia
Highest Development Status: Approved
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 11, 2021
Details:
The findings suggest that CoronaVac® has a good safety profile among the healthy pediatric and adolescent population ranging from 3 to 17 years old.
Lead Product(s):
Inactivated SARS-CoV-2 Virus
Therapeutic Area: Infections and Infectious Diseases
Product Name: CoronaVac
Highest Development Status: Approved
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 09, 2021
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
